-
Je něco špatně v tomto záznamu ?
Three-month course of intragraft transcriptional changes in kidney allografts with early histological minimal injury - a cohort study
P. Hruba, K. Madill-Thomsen, M. Mackova, J. Maluskova, L. Voska, J. Slatinska, PF. Halloran, O. Viklicky
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
17-28778A
Ministry of Health of the Czech Republic
NV19-06-00031
Ministry of Health of the Czech Republic
NV17-28778A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
Medline Complete (EBSCOhost)
od 2004-05-01
ROAD: Directory of Open Access Scholarly Resources
od 1988
PubMed
33650206
DOI
10.1111/tri.13856
Knihovny.cz E-zdroje
- MeSH
- alografty MeSH
- biopsie MeSH
- kohortové studie MeSH
- ledviny MeSH
- lidé MeSH
- rejekce štěpu * MeSH
- transplantace ledvin * škodlivé účinky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
The tubulitis with/without interstitial inflammation not meeting criteria for T-cell-mediated rejection (minimal allograft injury) is the most frequent histological findings in early transplant biopsies. The course of transcriptional changes in sequential kidney graft biopsies has not been studied yet. Molecular phenotypes were analyzed using the Molecular Microscope® Diagnostic System (MMDx) in 46 indication biopsies (median 13 postoperative days) diagnosed as minimal allograft injury and in corresponding follow-up biopsies at 3 months. All 46 patients with minimal injury in early biopsy received steroid pulses. MMDx interpreted indication biopsies as no-rejection in 34/46 (74%), T-cell-mediated rejection (TCMR) in 4/46 (9%), antibody-mediated rejection in 6/46 (13%), and mixed rejection in 2/46 (4%) cases. Follow-up biopsies were interpreted by MMDx in 37/46 (80%) cases as no-rejection, in 4/46 (9%) as TCMR, and in 5/46 (11%) as mixed rejection. Follow-up biopsies showed a decrease in MMDx-assessed acute kidney injury (P = 0.001) and an increase of atrophy-fibrosis (P = 0.002). The most significant predictor of MMDx rejection scores in follow-up biopsies was the tubulitis classifier score in initial biopsies (AUC = 0.84, P = 0.002), confirmed in multivariate binary regression (OR = 16, P = 0.016). Molecular tubulitis score at initial biopsy has the potential to discriminate patients at risk for molecular rejection score at follow-up biopsy.
Alberta Transplant Applied Genomics Centre Edmonton AB Canada
Department of Pathology Institute for Clinical and Experimental Medicine Prague Czech Republic
Transplant Laboratory Institute for Clinical and Experimental Medicine Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21025819
- 003
- CZ-PrNML
- 005
- 20211026133454.0
- 007
- ta
- 008
- 211013s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/tri.13856 $2 doi
- 035 __
- $a (PubMed)33650206
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Hruba, Petra $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 245 10
- $a Three-month course of intragraft transcriptional changes in kidney allografts with early histological minimal injury - a cohort study / $c P. Hruba, K. Madill-Thomsen, M. Mackova, J. Maluskova, L. Voska, J. Slatinska, PF. Halloran, O. Viklicky
- 520 9_
- $a The tubulitis with/without interstitial inflammation not meeting criteria for T-cell-mediated rejection (minimal allograft injury) is the most frequent histological findings in early transplant biopsies. The course of transcriptional changes in sequential kidney graft biopsies has not been studied yet. Molecular phenotypes were analyzed using the Molecular Microscope® Diagnostic System (MMDx) in 46 indication biopsies (median 13 postoperative days) diagnosed as minimal allograft injury and in corresponding follow-up biopsies at 3 months. All 46 patients with minimal injury in early biopsy received steroid pulses. MMDx interpreted indication biopsies as no-rejection in 34/46 (74%), T-cell-mediated rejection (TCMR) in 4/46 (9%), antibody-mediated rejection in 6/46 (13%), and mixed rejection in 2/46 (4%) cases. Follow-up biopsies were interpreted by MMDx in 37/46 (80%) cases as no-rejection, in 4/46 (9%) as TCMR, and in 5/46 (11%) as mixed rejection. Follow-up biopsies showed a decrease in MMDx-assessed acute kidney injury (P = 0.001) and an increase of atrophy-fibrosis (P = 0.002). The most significant predictor of MMDx rejection scores in follow-up biopsies was the tubulitis classifier score in initial biopsies (AUC = 0.84, P = 0.002), confirmed in multivariate binary regression (OR = 16, P = 0.016). Molecular tubulitis score at initial biopsy has the potential to discriminate patients at risk for molecular rejection score at follow-up biopsy.
- 650 _2
- $a alografty $7 D064591
- 650 _2
- $a biopsie $7 D001706
- 650 _2
- $a kohortové studie $7 D015331
- 650 12
- $a rejekce štěpu $7 D006084
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ledviny $7 D007668
- 650 12
- $a transplantace ledvin $x škodlivé účinky $7 D016030
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Madill-Thomsen, Katelynn $u Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada $u University of Alberta, Edmonton, AB, Canada
- 700 1_
- $a Mackova, Martina $u Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada
- 700 1_
- $a Maluskova, Jana $u Department of Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Voska, Ludek $u Department of Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Slatinska, Janka $u Department of Nephrology and Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Halloran, Philip F $u Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada $u University of Alberta, Edmonton, AB, Canada
- 700 1_
- $a Viklicky, Ondrej $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Department of Nephrology and Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 773 0_
- $w MED00004553 $t Transplant international : official journal of the European Society for Organ Transplantation $x 1432-2277 $g Roč. 34, č. 5 (2021), s. 974-985
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33650206 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133500 $b ABA008
- 999 __
- $a ok $b bmc $g 1714738 $s 1146326
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 34 $c 5 $d 974-985 $e 20210316 $i 1432-2277 $m Transplant international $n Transpl Int $x MED00004553
- GRA __
- $a 17-28778A $p Ministry of Health of the Czech Republic
- GRA __
- $a NV19-06-00031 $p Ministry of Health of the Czech Republic
- GRA __
- $a NV17-28778A $p MZ0
- LZP __
- $a Pubmed-20211013